Proton Magnetic Resonance Spectroscopy in First Episode Psychosis and Ultra High-Risk Individuals

Schizophrenia Bulletin

Volumn 29, Issue 4, 2003, Pages 831-843

  Wood, Stephen J ^a,b,c   Berger, Gregor ^d   Velakoulis, Dennis ^b   Phillips, Lisa J ^d   McGorry, Patrick D ^d   Yung, Alison R ^d   Desmond, Patricia ^e   Pantelis, Christos ^b  

^a SUNSHINE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^d THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Dorsolateral prefrontal; Early psychosis; Medial temporal; MRS; Prodrome; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CHOLINE; CREATINE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; N ACETYLASPARTIC ACID; OLANZAPINE; RISPERIDONE;

CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FEMALE; HIGH RISK POPULATION; HUMAN; MALE; METABOLIC REGULATION; NERVE CELL; NEUROBIOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PSYCHOSIS; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE;

EID: 0842300435     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a007049     Document Type: Conference Paper

References (76)

1. Armstrong, E.; Schleicher, A.; Omran, H.; Curtis, M.; and Zilles, K. The ontogeny of human gyrification. Cerebral Cortex, 5:56-63, 1995.
2. Barch, D.M.; Carter, C.S.; Braver, T.S.; Sabb, F.W.; MacDonald, A.; Noll, D.; and Cohen, J.D. Selective deficits in prefrontal cortex function in medication-naive patients with schizophrenia. Archives of General Psychiatry, 58:280-288, 2001.
3. Bartha, R.; Al-Semaan, Y.M.; Williamson, P.C.; Drost, D.J.; Malla, A.K.; Carr, T.J.; Densmore, M.; Canaran, G.; and Neufeld, R.W. A short echo proton magnetic resonance resonance spectroscopy study of the left mesial-temporal lobe in first-onset schizophrenic patients. Biological Psychiatry, 45:1403-1411, 1999.
4. Benes, F.M. Myelination of cortical-hippocampal relays during late adolescence. Schizophrenia Bulletin, 15:585-593, 1989.
5. Berger, G.; Wood, S.J.; and McGorry, P.D. Incipient neurovulnerability and neuroprotection in early psychosis. Psychopharmacology Bulletin, 37:79-101, 2003.
6. Bertolino, A.; Callicott, J.H.; Mattay, V.S.; Weidenhammer, K.M.; Rakow, R.; Egan, M.; and Weinberger, D.R. The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biological Psychiatry, 49:39-46, 2001.
7. Bertolino, A.; Esposito, G.; Callicott, J.H.; Mattay, V.S.; Van Horn, J.D.; Frank, J.A.; Berman, K.F.; and Weinberger, D.R. Specific relationship between prefrontal neuronal N-Acetylaspartate and activation of the working memory cortical network in schizophrenia. American Journal of Psychiatry, 157:26-33, 2000.
8. Bertolino, A.; Sciota, D.; Brudaglio, F.; Altamura, M.; Blasi, G.; Bellomo, A.; Antonucci, N.; Callicott, J.H.; Goldberg, T.E.; Scarabino, T.; Weinberger, D.R.; and Nardini, M. Working memory deficits and levels of N-Acetylaspartate in patients with schizophreniform disorder. American Journal of Psychiatry, 160:483-489, 2003.
9. 1H NMR spectroscopic studies of the brain. Neuroscience and Biobehavioural Reviews, 13:23-31, 1989.
10. Block, W.; Bayer, T.A.; Tepest, R.; Träber, F.; Rietschel, M.; Müller, D.J.; Schulze, T.G.; Honer, W.G.; Maier, W.; Schild, H.H.; and Falkai, P. Decreased frontal lobe ratio of N-acetyl aspartate to choline in familial schizophrenia: A proton magnetic resonance spectroscopy study. Neuroscience Letters, 289:147-151, 2000.
11. Braus, D.F.; Ende, G.; Weber-Fahr, W.; Sartorius, A.; Krier, A.; Hubrich-Ungureanu, P.; Ruf, M.; Stuck, S.; and Henn, F.A. Antipsychotic drug effects on motor activation measured by functional magnetic resonance imaging in schizophrenic patients. Schizophrenia Research, 39(1):19-29, 1999.
12. Callicott, J.H.; Bertolino, A.; Egan, M.; Mattay, V.S.; Langheim, F.J.; and Weinberger, D.R. Selective relationship between prefrontal N-acetylaspartate measures and negative symptoms in schizophrenia. American Journal of Psychiatry, 157:1646-1651, 2000.
13. Callicott, J.H.; Egan, M.; Bertolino, A.; Mattay, V.S.; Langheim, F.J.; Frank, J.A.; and Weinberger, D.R. Hippocampal N-acetyl aspartate in unaffected siblings of patients with schizophrenia: A possible intermediate neurobiological phenotype. Biological Psychiatry, 44:941-950, 1998.
14. Chi, J.; Dooling, E.; and Gilles, F. Gyral development of the human brain. Annals of Neurology, 1:86-93, 1977.
15. Deicken, R.F.; Pegues, M.; and Amend, D. Reduced hippocampal N-acetylaspartate without volume loss in schizophrenia. Schizophrenia Research, 37:217-223, 1999.
16. First, M.B.; Spitzer, R.L.; Gibbon, M.; and Williams, J.B. Structured Clinical Interview for DSM-IV Axis I Disorders. Washington, DC: American Psychiatric Press, 1997.
17. Gur, R.E.; Cowell, P.; Latshaw, A.; Turetsky, B.I.; Grossman, R.I.; Arnold, S.E.; Bilker, W.; and Gur, R.C. Reduced dorsal and orbital prefrontal gray matter volumes in schizophrenia. Archives of General Psychiatry, 57:761-768, 2000.
18. Harrison, P.J. The neuropathology of schizophrenia: A critical review of the data and their interpretation. Brain, 122:593-624, 1999.
19. Honey, G.D.; Bullmore, E.T.; Soni, W.; Varatheesan, M.; Williams, S.C.; and Sharma, T. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 96(23):13432-13437, 1999.
20. 2) of the proton MRS creatine resonance in human brain. Magnetic Resonance in Medicine, 47:232-238, 2002.
21. Ke, Y.; Coyle, J.T.; Simpson, N.; Gruber, S.A.; Renshaw, P.F.; and Yurgelun-Todd, D. Frontal brain NAA T2 values are significantly lower in schizophrenia. Schizophrenia Research, 60:242, 2003.
22. Keshavan, M.S.; Montrose, D.M.; Pierri, J.N.; Dick, E.L.; Rosenberg, D.; Talagala, L.; and Sweeney, J.A. Magnetic resonance imaging and spectroscopy in offspring at risk for schizophrenia: Preliminary studies. Progress in Neuro-Psychopharmacology Biological Psychiatry, 21:1285-1295, 1997.
23. Keshavan, M.S.; Stanley, J.A.; and Pettegrew, J.W. Magnetic resonance spectroscopy in schizophrenia: Methodological issues and findings-Part II. Biologica Psychiatry, 48:369-380, 2000.
24. Kulynych, J.; Luevano, L.; Jones, D.; and Weinberger, D.R. Cortical abnormality in schizophrenia: An in vivo application of the gyrification index. Biological Psychiatry, 41:995-999, 1997.
25. Lawrie, S.M.; Whalley, H.; Kestelman, J.N.; Abukmeil, S.S.; Byrne, M.; Hodges, A.; Rimmington, J.E.; Best, J.J.; Owens, D.G.; and Johnstone, E.C. Magnetic resonance imaging of brain in people at high risk of developing schizophrenia. The Lancet, 353:30-33, 1999.
26. Liddle, P.F.; Lane, C.J.; and Ngan, E.T. Immediate effects of risperidone on cortico-striato-thalamic loops and the hippocampus. British Journal of Psychiatry, 177:402-407, 2000.
27. Lieberman, J.A.; Alvir, J.M.; Koreen, A.; Geisler, S.; Chakos, M.; Sheitman, B.B.; and Woerner, M.G. Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology, 14:13S-21S, 1996.
28. Lieberman, J.A.; Perkins, D.; Belger, A.; Chakos, M.; Jarskog, F.; Boteva, K.; and Gilmore, J. The early stages of schizophrenia: Speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biological Psychiatry, 50:884-897, 2001.
29. Maier, M.; Mellers, J.; Toone, B.K.; Trimble, M.; and Ron, M.A. Schizophrenia, temporal lobe epilepsy and psychosis: An in vivo magnetic resonance spectroscopy and imaging study of the hippocampus/amygdala complex. Psychological Medicine, 30:571-581, 2000.
30. Marenco, S., and Weinberger, D.R. The neurodevelopmental hypothesis of schizophrenia: Following a trail of evidence from cradle to grave. Development and Psychopathology, 12:501-527, 2000.
31. McCarley, R.W.; Wible, C.G.; Frumin, M.; Hirayasu, Y.; Fischer, I.A.; and Shenton, M.E. MRI anatomy of schizophrenia. Biological Psychiatry, 45:1085-1098, 1999.
32. McGlashan, T.H., and Hoffman, R.E. Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Archives of General Psychiatry, 57:637-648, 2000.
33. McGorry, P.D.; Edwards, J.; Mihalopoulos, C.; Harrigan, S.; and Jackson, H. EPPIC-An evolving system of early detection and optimal management. Schizophrenia Bulletin, 22:305-326, 1996.
34. McGorry, P.D.; Kaplan, I.; Dossestor, C.; Herman, H.; Copolov, D.; and Singh, B. Royal Park Multidiagnostic Instrument for Psychosis. Melbourne: Australian National Health and Medical Research Council, 1989.
35. McGorry, P.D.; Phillips, L.J.; and Yung, A.R. Recognition and treatment of the pre-psychotic phase of psychotic disorders: Frontier or fantasy? In: Miller, T.; Mednick, S.A.; McGlashan, T.H.; Libiger, J.; and Johanssen, J., eds. Early Intervention in Psychiatric Disorders. Amsterdam, Netherlands: Kluwer, 2001a. pp. 101-122.
36. McGorry, P.D.; Yung, A.R.; and Phillips, L.J. 'Closing in': What features predict the onset of first episode psychosis within a high risk group? In: Zipursky, R., and Schulz, S.C., eds. The Early Stages of Schizophrenia. Washington, DC: American Psychiatric Press, 2001b. pp. 3-32.
37. McGorry, P.D.; Yung, A.R.; Phillips, L.J.; Yuen, H.P.; Francey, S.; Cosgrave, E.; Germano, D.; Bravin, J.; McDonald, A.; Blair, A.; Adlard, S.; and Jackson, H.J. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry, 59:921-928, 2002.
38. McGrath, J.; Van Os, J.; Hoyos, C.; Jones, P.; Harvey, I.; and Murray, R.M. Minor physical anomalies in psychoses: Associations with clinical and putative aetiological variables. Schizophrenia Research, 18:9-20, 1995.
39. Mervaala, E.; Föhr, J.; Könönen, M.; Valkonen-Korhonen, M.; Vainio, P.; Partanen, K.; Partanen, J.; Tiihonen, J.; Viinamäki, H.; Karjalainen, A.; and Lehtonen, J. Quantitative MRI of the hippocampus and amygdala in severe depression. Psychological Medicine, 30:117-126, 2000.
40. Murray, R.M., and Lewis, S. Is schizophrenia a neurodevelopmental disorder? [Editorial]. British Medical Journal, 295:681-682, 1987.
41. Narr, K.L.; Thompson, P.; Sharma, T.; Moussai, J.; Zoumalan, C.; Rayman, J.; and Toga, A. Three-dimensional mapping of gyral shape and cortical surface asymmetries in schizophrenia: Gender effects. American Journal of Psychiatry, 158:244-255, 2001.
42. Nelson, H.E., and Willison, J.R. Restandardisation of the NART against the WAIS-R. In: Nelson, H.E., ed. National Adult Reading Test (NART) Test Manual. Windsor, U.K.: NFER-Nelson, 1991. pp. 13-23.
43. Nelson, M.D.; Saykin, A.J.; Flashman, L.A.; and Riordan, H.J. Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging: A meta-analytic study. Archives of General Psychiatry, 55:433-440, 1998.
44. Oppenheimer, D. Diseases of the basal ganglia, cerebellum, and motor neurons. In: Adams, J.; Corsellis, J.; and Duchen, L., eds. Greenfield's Neuropathology. New York, NY: Wiley, 1984. pp. 699-747.
45. Pantelis, C. Overview: Towards a neuropsychology of schizophrenia. In: Pantelis, C.; Nelson, H.E.; and Barnes, T.R., eds. Schizophrenia: A Neuropsychological Perspective. London, UK: John Wiley & Sons, 1996. pp. 3-18.
46. Pantelis, C.; Velakoulis, D.; McGorry, P.D.; Wood, S.J.; Suckling, J.; Phillips, L.J.; Yung, A.R.; Bullmore, E.T.; Brewer, W.J.; Soulsby, B.; Desmond, P.; and McGuire, P.K. Neuroanatomical abnormalities before and after onset of psychosis: A cross-sectional and longitudinal MRI study. The Lancet, 361:281-288, 2003a.
47. Pantelis, C.; Wood, S.J.; Tarnawski, A.; Proffitt, T.; Francey, S.; Brewer, W.J.; Phillips, L.J.; Savage, G.R.; Smith, D.; Anderson, V.; and McGorry, P.D. Verbal paired associate learning in schizophrenia, schizophreniform psychosis and 'at risk' mental state. Schizophrenia Research, 60:151-152, 2003b.
48. Pantelis, C.; Yücel, M.; Wood, S.J.; McGorry, P.D.; and Velakoulis, D. Early and late neurodevelopmental disturbances in schizophrenia and their functional consequences. Australian and New Zealand Journal of Psychiatry, 37:399-406, 2003c.
49. Pettegrew, J.W.; Keshavan, M.S.; Panchalingam, K.; Strychor, S.; Kaplan, D.; Tretta, M.; and Allen, M. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Archives of General Psychiatry, 48:563-568, 1991.
50. Phillips, L.J.; Velakoulis, D.; Pantelis, C.; Wood, S.J.; Yuen, H.P.; Yung, A.R.; Desmond, P.; Brewer, W.J.; and McGorry, P.D. Non-reduction in hippocampal volume is associated with risk for psychosis. Schizophrenia Research, 58:145-158, 2002.
51. Phillips, L.J.; Yung, A.R.; and McGorry, P.D. Identification of young people at risk of psychosis: Validation of Personal Assessment and Crisis Evaluation Clinic intake criteria. Australian and New Zealand Journal of Psychiatry, 34 (Suppl):S164-S169, 2000.
52. Provencher, S. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magnetic Resonance in Medicine, 30:672-679, 1993.
53. Robinson, D.; Woerner, M.G.; Alvir, J.M.; Geisler, S.; Koreen, A.; Sheitman, B.B.; Chakos, M.; Mayerhoff, D.; Bilder, R.M.; Goldman, R.; and Lieberman, J.A. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry, 156:544-549, 1999.
54. Rossi, A.; Bustini, M.; Prosperini, P.; Marinangeli, M.; Splendiani, A.; Daneluzzo, E.; and Stratta, P. Neuromorphological abnormalities in schizophrenic patients with good and poor outcome. Acta Psychiatrica Scandanavia, 101:161-166, 2000.
55. Sawrie, S.M.; Martin, R.C.; Knowlton, R.C.; Faught, E.; Gilliam, F.G.; and Kuzniecky, R. Relationships among hippocampal volumetry, proton magnetic resonance spectroscopy, and verbal memory in temporal lobe epilepsy. Epilepsia, 42:1403-1407, 2001.
56. Schuff, N.; Neylan, T.; Lenoci, M.; Du, A.; Weiss, D.; Marmar, C.; and Weiner, M. Decreased hippocampal N-acetylaspartate in the absence of atrophy in posttraumatic stress disorder. Biological Psychiatry, 50:952-959, 2001.
57. Španiel, F.; Hájek, T.; Tintera, J.; Harantová, P.; Dezortová, M.; and Hájek, M. Differences in fMRI and MRS in a monozygotic twin pair discordant for schizophrenia (case report). Acta Psychiatrica Scandanavia, 107:155-158, 2003.
58. Stanley, J.A.; Williamson, P.; Drost, D.J.; Carr, T.J.; Rylett, R.; Malla, A.K.; and Thompson, R. An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy. Archives of General Psychiatry, 52:399-406, 1995.
59. Stanley, J.A.; Williamson, P.C.; Drost, D.; Rylett, R.; Carr, T.J.; Malla, A.K.; and Thompson, R. An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients. Schizophrenia Bulletin, 22:597-609, 1996.
60. Urenjak, J.; Williams, S.R.; Gadian, D.G.; and Noble, M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. Journal of Neuroscience, 13(3):981-989, 1993.
61. van Os, J.; Jones, P.; Lewis, G.; Wadsworth, M.; and Murray, R. Developmental precursors of affective illness in a general population birth cohort. Arch Gen Psychiatry, 54(7):625-631, 1997.
62. Velakoulis, D.; Pantelis, C.; McGorry, P.D.; Dudgeon, P.; Brewer, W.J.; Cook, M.J.; Desmond, P.; Bridle, N.; Tierney, P.; Murrie, V.; Singh, B.; and Copolov, D. Hippocampal volume in first-episode psychoses and chronic schizophrenia: A high-resolution magnetic resonance imaging study. Archives of General Psychiatry, 56:133-140, 1999.
63. Vogeley, K.; Schneider-Axmann, T.; Pfeiffer, U.; Tepest, R.; Bayer, T.A. ; Bogerts, B.; Honer, W.G.; and Falkai, P. Disturbed gyrification of the prefrontal region in male schizophrenic patients: A morphometric postmortem study. American Journal of Psychiatry, 157:34-39, 2000.
64. Walker, E.; Savoie, T.; and Davis, D. Neuromotor precursors of schizophrenia. Schizophrenia Bulletin, 20:441-451, 1994.
65. Wassink, T.H.; Andreasen, N.C.; Nopoulos, P.; and Flaum, M. Cerebellar morphology as a predictor of symptom and psychosocial outcome in schizophrenia. Biological Psychiatry, 45:41-48, 1999.
66. Weinberger, D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Archives of General Psychiatry, 44:660-669, 1987.
67. Wood, S.J.; De Luca, C.R.; Anderson, V.; and Pantelis, C. Cognitive development in adolescence: Cerebral underpinnings, neural trajectories and the impact of aberrations. In: Keshavan, M.S.; Kennedy, J.L.; and Murray, R.M., eds. The Developmental Trajectory to Schizophrenia: From Neurodevelopmental Deviance to Psychotic Syndrome. Cambridge, U.K.: Cambridge University Press, in press.
68. Wood, S.J., and Pantelis, C. Does a neurodevelopmental lesion involving the hippocampus explain memory dysfunction in schizophrenia? Zeitschrift für Neuropsychologie, 12(1):61-67, 2001.
69. Wood, S.J.; Pantelis, C.; Proffitt, T.; Phillips, L.J.; Stuart, G.W.; Buchanan, J.-A.; Mahony, K.; Brewer, W.J.; Smith, D.; and McGorry, P.D. Spatial working memory ability is a marker of risk-for-psychosis. Psychological Medicine, 33:1239-1247, 2003.
70. Worthen, N.; Gilbertson, V.; and Lau, C. Cortical sulcal development seen on sonography: Relationship to gestational parameters. Journal of Ultrasound in Medicine, 5:153-156, 1986.
71. Yücel, M.; Stuart, G.W.; Maruff, P.; Wood, S.J.; Savage, G.; Smith, D.; Crowe, S.F.; Copolov, D.; Velakoulis, D.; and Pantelis, C. Paracingulate morphologic differences in males with established schizophrenia: A magnetic resonance imaging morphometric study. Biological Psychiatry, 52:15-23, 2002.
72. Yücel, M.; Wood, S.J.; Phillips, L.J.; Stuart, G.W.; Smith, D.; Yung, A.R.; Velakoulis, D.; McGorry, P.D.; and Pantelis, C. Morphological anomalies of the anterior cingulate cortex in young individuals at ultra high-risk of developing a psychotic illness. British Journal of Psychiatry, 182:518-524, 2003.
73. Yung, A.R.; McGorry, P.D.; McFarlane, C.A.; Jackson, H.J.; Patton, G.C.; and Rakkar, A. Monitoring and care of young people at incipient risk of psychosis. Schizophrenia Bulletin, 22:283-303, 1996.
74. Yung, A.R.; Phillips, L.J.; Yuen, H.P.; Francey, S.; McFarlane, C.A.; Hallgren, M.; and McGorry, P.D. Psychosis prediction: 12 month follow-up of a high risk ('prodromal') group. Schizophrenia Research, 60(1):21-32, 2003.
75. Yung, A.R.; Yuen, H.P.; McGorry, P.D.; Hallgren, M.; McFarlane, C.A.; Jackson, H.J.; Francey, S.; and Patton, G.C. Can we predict onset of first episode psychosis in a high risk group? International Clinical Psychopharmacology, 13:S23-S30, 1998.
76. Zilles, K.; Armstrong, E.; Schleicher, A.; and Kretschmann, H. The human pattern of gyrification in the cerebral cortex. Anatomy and Embryology, 179:173-179, 1988.